$87.79
0.37% today
Nasdaq, Feb 05, 04:47 pm CET
ISIN
US2521311074
Symbol
DXCM
Sector

DexCom, Inc. Stock price

$87.46
+7.58 9.49% 1M
+15.03 20.75% 6M
+9.69 12.46% YTD
-33.77 27.86% 1Y
-17.63 16.77% 3Y
+26.54 43.55% 5Y
+72.21 473.60% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.41 0.47%
ISIN
US2521311074
Symbol
DXCM
Sector

Key metrics

Market capitalization $34.16b
Enterprise Value $34.26b
P/E (TTM) P/E ratio 52.43
EV/FCF (TTM) EV/FCF 64.04
EV/Sales (TTM) EV/Sales 8.66
P/S ratio (TTM) P/S ratio 8.64
P/B ratio (TTM) P/B ratio 17.26
Revenue growth (TTM) Revenue growth 16.19%
Revenue (TTM) Revenue $3.95b
EBIT (operating result TTM) EBIT $628.00m
Free Cash Flow (TTM) Free Cash Flow $535.00m
Cash position $2.49b
EPS (TTM) EPS $1.67
P/E forward 57.04
P/S forward 8.49
EV/Sales forward 8.52
Short interest 2.55%
Show more

Create a Free Account to create an DexCom, Inc. alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

DexCom, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a DexCom, Inc. forecast:

22x Buy
85%
4x Hold
15%

Analyst Opinions

26 Analysts have issued a DexCom, Inc. forecast:

Buy
85%
Hold
15%

Financial data from DexCom, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
3,954 3,954
16% 16%
100%
- Direct Costs 1,513 1,513
22% 22%
38%
2,441 2,441
13% 13%
62%
- Selling and Administrative Expenses 1,055 1,055
5% 5%
27%
- Research and Development Expense 546 546
12% 12%
14%
840 840
24% 24%
21%
- Depreciation and Amortization 212 212
25% 25%
5%
EBIT (Operating Income) EBIT 628 628
24% 24%
16%
Net Profit 681 681
81% 81%
17%

In millions USD.

Don't miss a Thing! We will send you all news about DexCom, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

DexCom, Inc. Stock News

Neutral
The Motley Fool
2 days ago
Medical device specialist DexCom (DXCM -0.90%) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to unimpressive financial results, especially in the second and third quarters.
Positive
The Motley Fool
2 days ago
The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the performance of many top stocks reflects this reality. However, a share price moving upward or downward should never be the sole reason you buy (or sell) stocks.
Neutral
Business Wire
6 days ago
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2025. Management will hold a conference call to review the company's fourth quarter and fiscal year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be...
More DexCom, Inc. News

Company Profile

DexCom, Inc. is a medical device manufacturing company. The firm engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, DexCom G5 Mobil, DexCom Share and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Head office United States
CEO Kevin Sayer
Employees 9,600
Founded 1999
Website www.dexcom.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today